Oramed Pharmaceuticals Company Profile (NASDAQ:ORMP)

About Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals logoOramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ORMP
  • CUSIP: N/A
  • Web: www.oramed.com
Capitalization:
  • Market Cap: $114.06 million
  • Outstanding Shares: 13,294,000
Average Prices:
  • 50 Day Moving Avg: $7.29
  • 200 Day Moving Avg: $6.51
  • 52 Week Range: $5.70 - $9.09
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.74 million
  • Price / Sales: 65.55
  • Book Value: $1.60 per share
  • Price / Book: 5.36
Profitability:
  • EBIDTA: ($11,410,000.00)
  • Return on Equity: -39.09%
  • Return on Assets: -27.40%
Debt:
  • Current Ratio: 6.45%
  • Quick Ratio: 6.45%
Misc:
  • Average Volume: 36,092 shs.
  • Beta: 0.44
  • Short Ratio: 10.21
 

Frequently Asked Questions for Oramed Pharmaceuticals (NASDAQ:ORMP)

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Where is Oramed Pharmaceuticals' stock going? Where will Oramed Pharmaceuticals' stock price be in 2017?

3 brokers have issued 1 year price objectives for Oramed Pharmaceuticals' stock. Their predictions range from $20.00 to $25.00. On average, they expect Oramed Pharmaceuticals' share price to reach $23.33 in the next year. View Analyst Ratings for Oramed Pharmaceuticals.

Who are some of Oramed Pharmaceuticals' key competitors?

Who owns Oramed Pharmaceuticals stock?

Oramed Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include PNC Financial Services Group Inc. (0.16%). Company insiders that own Oramed Pharmaceuticals stock include Michael Berelowitz, Miriam Kidron and Nadav Kidron. View Institutional Ownership Trends for Oramed Pharmaceuticals.

How do I buy Oramed Pharmaceuticals stock?

Shares of Oramed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Oramed Pharmaceuticals stock cost?

One share of Oramed Pharmaceuticals stock can currently be purchased for approximately $8.58.

Analyst Ratings

Consensus Ratings for Oramed Pharmaceuticals (NASDAQ:ORMP) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.33 (171.95% upside)

Analysts' Ratings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/22/2017HC WainwrightSet Price TargetBuy$25.00LowView Rating Details
8/21/2016Rodman & RenshawReiterated RatingBuy$25.00N/AView Rating Details
5/26/2016FBR & CoBoost Price TargetOutperform$15.00 -> $20.00N/AView Rating Details
5/18/2016AegisReiterated RatingBuy$18.00N/AView Rating Details
7/8/2015MLV & Co.Reiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)
Current Year EPS Consensus Estimate: $-0.62 EPS
Next Year EPS Consensus Estimate: $-1.01 EPS

Dividends

Dividend History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Oramed Pharmaceuticals (NASDAQ:ORMP)
Insider Ownership Percentage: 25.90%
Institutional Ownership Percentage: 0.83%
Insider Trades by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)
Institutional Ownership by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)
Insider Trades by Quarter for Oramed Pharmaceuticals (NASDAQ:ORMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/19/2017Miriam KidronInsiderSell52,814$6.33$334,312.62View SEC Filing  
5/12/2016Nadav KidronCEOBuy1,000$6.95$6,950.00View SEC Filing  
12/30/2015Miriam KidronCTOSell50,000$8.90$445,000.00View SEC Filing  
12/9/2015Michael BerelowitzDirectorSell700$9.44$6,608.00View SEC Filing  
12/8/2015Michael BerelowitzDirectorSell1,300$8.70$11,310.00View SEC Filing  
3/19/2015Nadav KidronCEOBuy2,600$3.88$10,088.00View SEC Filing  
9/11/2014Miriam KidronCTOSell31,699$8.41$266,588.59View SEC Filing  
9/10/2014Miriam KidronCTOSell23,000$8.40$193,200.00View SEC Filing  
9/4/2014Miriam KidronCTOSell8,301$9.41$78,112.41View SEC Filing  
6/6/2014Regals Capital Management LpMajor ShareholderBuy2,252$4.44$9,998.88View SEC Filing  
3/31/2014Michael BerelowitzDirectorSell9,434$10.50$99,057.00View SEC Filing  
3/25/2014Regals Capital Management Lpmajor shareholderBuy75,000$10.62$796,500.00View SEC Filing  
2/6/2014Regals Capital Management Lpmajor shareholderBuy51,292$15.61$800,668.12View SEC Filing  
7/10/2013Regals Capital Management LpMajor ShareholderBuy6,630$7.40$49,062.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Oramed Pharmaceuticals (NASDAQ:ORMP)
Latest Headlines for Oramed Pharmaceuticals (NASDAQ:ORMP)
Source:
DateHeadline
finance.yahoo.com logoOramed to Present at Conferences Next Week
finance.yahoo.com - May 19 at 11:50 AM
streetinsider.com logoOramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul - StreetInsider.com
www.streetinsider.com - May 10 at 11:49 AM
streetinsider.com logoOramed Pharma (ORMP) Announces Canadian Patent for GLP-1 Analog Capsul
www.streetinsider.com - May 9 at 11:16 AM
finance.yahoo.com logoOramed Granted Canadian Patent for GLP-1 Analog Capsule
finance.yahoo.com - May 9 at 11:16 AM
finance.yahoo.com logoOramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017
finance.yahoo.com - May 5 at 7:20 PM
finance.yahoo.com logoOramed (ORMP) to Conduct Human Study for New Oral Leptin Capsule
finance.yahoo.com - May 2 at 4:51 PM
prnewswire.com logoOramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule - PR Newswire (press release)
www.prnewswire.com - May 2 at 11:10 AM
finance.yahoo.com logoOramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule
finance.yahoo.com - May 2 at 11:10 AM
finance.yahoo.com logoOramed Gaining Strength in Oral Diabetes Market
finance.yahoo.com - May 1 at 5:58 PM
streetinsider.com logoOramed Pharma (ORMP) Says EPO Granted Patent for Combination Oral Insulin and GLP-1 Analog Capsule - StreetInsider.com
www.streetinsider.com - April 21 at 12:12 AM
finance.yahoo.com logoOramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule - Yahoo Finance
finance.yahoo.com - April 20 at 9:04 AM
finance.yahoo.com logoOramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule
finance.yahoo.com - April 20 at 9:04 AM
americanbankingnews.com logoInsider Selling: Oramed Pharmaceuticals, Inc. (ORMP) Insider Sells 52,814 Shares of Stock
www.americanbankingnews.com - April 19 at 7:53 PM
marketbeat.com logoOramed reports 2Q loss
marketbeat.com - April 6 at 5:04 AM
finance.yahoo.com logoOramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017
finance.yahoo.com - March 22 at 9:02 AM
streetinsider.com logoOramed Pharma (ORMP) Appoints Dr. Ronald Law as CSO - StreetInsider.com
www.streetinsider.com - March 21 at 11:12 AM
finance.yahoo.com logoOramed Appoints Dr. Ronald Law as Chief Strategy Officer
finance.yahoo.com - March 21 at 11:12 AM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 21 at 11:12 AM
seekingalpha.com logoHere's Where Oramed Fits Into The Diabetes Space
seekingalpha.com - February 17 at 4:45 PM
finance.yahoo.com logoWhile Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever
finance.yahoo.com - February 9 at 8:13 PM
finance.yahoo.com logoOramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences
finance.yahoo.com - February 7 at 9:05 AM
finance.yahoo.com logoOramed reports 1Q loss - Yahoo Finance
finance.yahoo.com - January 12 at 5:48 AM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - January 11 at 7:44 PM
247wallst.com logo3 Sleeper Biotechs That Could Bounce Back Strong in 2017 - 24/7 Wall St.
247wallst.com - December 31 at 6:48 PM
finance.yahoo.com logoORAMED PHARMACEUTICALS INC. Financials
finance.yahoo.com - December 1 at 6:57 PM
finance.yahoo.com logoORMP: Oramed Reports Positive Phase Ib Data for ORMD-0901
finance.yahoo.com - November 30 at 7:12 PM
streetinsider.com logoOramed Pharma (ORMP) Completes ORMD-0901 Phase 1b; No Serious Adverse Events Noted - StreetInsider.com
www.streetinsider.com - November 29 at 2:17 PM
finance.yahoo.com logoOramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study
finance.yahoo.com - November 29 at 2:16 PM
finance.yahoo.com logo8:31 am Oramed Pharmaceuticals announces phase Ib study results of ORMD-0901 found it to be safe and well-tolerated
finance.yahoo.com - November 29 at 2:16 PM
biz.yahoo.com logoORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - November 25 at 11:55 AM
investorplace.com logo17 Pharmaceuticals Stocks to Sell Now - Investorplace.com
investorplace.com - November 18 at 6:17 PM

Social

Chart

Oramed Pharmaceuticals (ORMP) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff